Ross Osborn
Stock Analyst at Cantor Fitzgerald
(1.98)
# 3,119
Out of 5,113 analysts
119
Total ratings
31.82%
Success rate
-3.28%
Average return
Main Sectors:
Stocks Rated by Ross Osborn
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CVRX CVRx, Inc. | Maintains: Overweight | $11 → $13 | $7.33 | +77.35% | 4 | Nov 6, 2025 | |
| PRE Prenetics Global | Maintains: Overweight | $26 → $32 | $18.35 | +74.39% | 8 | Oct 29, 2025 | |
| ORGO Organogenesis Holdings | Maintains: Overweight | $7 → $9 | $3.95 | +127.85% | 4 | Aug 8, 2025 | |
| LMAT LeMaitre Vascular | Maintains: Neutral | $92 → $95 | $85.26 | +11.42% | 2 | Aug 6, 2025 | |
| SIBN SI-BONE | Reiterates: Overweight | $25 | $17.14 | +45.86% | 10 | Aug 5, 2025 | |
| MDXG MiMedx Group | Maintains: Overweight | $11 → $12 | $5.25 | +128.57% | 5 | Jul 31, 2025 | |
| BVS Bioventus | Initiates: Overweight | $12 | $7.89 | +52.09% | 1 | Jul 7, 2025 | |
| XGN Exagen | Maintains: Overweight | $8 → $7 | $4.41 | +58.73% | 6 | May 15, 2025 | |
| LUCD Lucid Diagnostics | Reiterates: Overweight | $2 | $1.23 | +62.60% | 6 | May 15, 2025 | |
| NPCE NeuroPace | Reiterates: Overweight | $17 | $16.23 | +4.74% | 7 | May 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $12 → $9 | $3.01 | +199.00% | 11 | Apr 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $46 | $21.25 | +116.47% | 6 | Mar 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $8 | $0.93 | +764.40% | 10 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $24 | $34.72 | -30.88% | 3 | Mar 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $4 | $2.46 | +62.60% | 4 | Feb 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $9 | $6.29 | +43.08% | 1 | Jan 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $21 | $4.53 | +363.58% | 10 | Dec 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $16 | $4.75 | +236.84% | 4 | Nov 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $3.5 | $2.52 | +38.89% | 5 | Aug 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $2.5 | $0.27 | +836.33% | 3 | May 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | n/a | $1.30 | - | 7 | Apr 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $258 | $9.34 | +2,665.52% | 2 | Aug 18, 2023 |
CVRx, Inc.
Nov 6, 2025
Maintains: Overweight
Price Target: $11 → $13
Current: $7.33
Upside: +77.35%
Prenetics Global
Oct 29, 2025
Maintains: Overweight
Price Target: $26 → $32
Current: $18.35
Upside: +74.39%
Organogenesis Holdings
Aug 8, 2025
Maintains: Overweight
Price Target: $7 → $9
Current: $3.95
Upside: +127.85%
LeMaitre Vascular
Aug 6, 2025
Maintains: Neutral
Price Target: $92 → $95
Current: $85.26
Upside: +11.42%
SI-BONE
Aug 5, 2025
Reiterates: Overweight
Price Target: $25
Current: $17.14
Upside: +45.86%
MiMedx Group
Jul 31, 2025
Maintains: Overweight
Price Target: $11 → $12
Current: $5.25
Upside: +128.57%
Bioventus
Jul 7, 2025
Initiates: Overweight
Price Target: $12
Current: $7.89
Upside: +52.09%
Exagen
May 15, 2025
Maintains: Overweight
Price Target: $8 → $7
Current: $4.41
Upside: +58.73%
Lucid Diagnostics
May 15, 2025
Reiterates: Overweight
Price Target: $2
Current: $1.23
Upside: +62.60%
NeuroPace
May 14, 2025
Reiterates: Overweight
Price Target: $17
Current: $16.23
Upside: +4.74%
Apr 1, 2025
Maintains: Overweight
Price Target: $12 → $9
Current: $3.01
Upside: +199.00%
Mar 26, 2025
Reiterates: Overweight
Price Target: $46
Current: $21.25
Upside: +116.47%
Mar 7, 2025
Reiterates: Overweight
Price Target: $8
Current: $0.93
Upside: +764.40%
Mar 5, 2025
Reiterates: Overweight
Price Target: $24
Current: $34.72
Upside: -30.88%
Feb 21, 2025
Reiterates: Overweight
Price Target: $4
Current: $2.46
Upside: +62.60%
Jan 7, 2025
Initiates: Overweight
Price Target: $9
Current: $6.29
Upside: +43.08%
Dec 24, 2024
Reiterates: Overweight
Price Target: $21
Current: $4.53
Upside: +363.58%
Nov 5, 2024
Reiterates: Overweight
Price Target: $16
Current: $4.75
Upside: +236.84%
Aug 8, 2024
Reiterates: Overweight
Price Target: $3.5
Current: $2.52
Upside: +38.89%
May 16, 2024
Reiterates: Overweight
Price Target: $2.5
Current: $0.27
Upside: +836.33%
Apr 12, 2024
Reiterates: Neutral
Price Target: n/a
Current: $1.30
Upside: -
Aug 18, 2023
Reiterates: Neutral
Price Target: $258
Current: $9.34
Upside: +2,665.52%